A Phase 2 interventional study of ZG005 for Injection and Bevacizumab in Hepatocellular Carcinoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing sintilimab in Carcinoma, Hepatocellular — 26 open to participants now, 30 under way, 5 of them phase 3. sintilimab · Carcinoma, Hepatocellular.
Among the 51 studies testing sintilimab in Carcinoma, Hepatocellular, this one is the 12th largest by planned enrollment, is one of 6 that started in 2024, is one of 30 in phase 2, reaches primary completion later than 18 of the 29 other live ones, and was the 42nd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →26 of the 51 studies testing sintilimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
TaiRx, Inc. · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Zhejiang University · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 36 · Phase 3 6
First in 2018; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 43 across the 51 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 51 have an industry lead sponsor. The 10 most frequent:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 4 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
7 of the studies testing sintilimab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186621Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdjuvant Radiotherapy of Sintilimab Versus TACE for HCC | 2027-07-09 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT06031285Sun Yat-sen UniversityPerioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial | 2026-12-30 |
| NCT07560488Tianjin Medical University Cancer Institute and HospitalIpilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | 2027-04 |
| NCT06995105Zhejiang UniversityPersonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 51 studies testing sintilimab in Carcinoma, Hepatocellular, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZG005 10 mg/kg administered intravenously every 3 weeks (Q3w) + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
Biological: ZG005 for Injection · Biological: Bevacizumab
ZG005 20 mg/kg administered intravenously Q3w + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
Biological: ZG005 for Injection · Biological: Bevacizumab
Sintilimab 200 mg administered intravenously Q3w + Bevacizumab (达攸同®) 15 mg/kg administered intravenously Q3w
Biological: Sintilimab · Biological: Bevacizumab
10 mg/kg or 20 mg/kg administered intravenously Q3w
Also known as: ZG005
15 mg/kg administered intravenously Q3w
Also known as: Avastin
200 mg administered intravenously Q3w
15 mg/kg administered intravenously Q3w
Also known as: 达攸同
progression free survival,PFS
defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first.
Time frame: through study completion, up to 2 year
Started Oct 2024 (actual). Primary completion is estimated for Sep 2026, 23 months after the start.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 23 months is below that.
Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nilvanstomig · Sintilimab
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →